Cargando…

Intervening TNF-α via PPARγ with Gegenqinlian Decoction in Experimental Nonalcoholic Fatty Liver Disease

This paper is to explore the effect and mechanism of Gegenqinlian decoction on experimental nonalcoholic fatty liver disease (NAFLD) in vivo and in vitro. The final aim is to make clear whether Gegenqinlian decoction would impact NAFLD through improving PPARγ to suppress inflammation and regulate li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yun-liang, Liu, Li-juan, Zhao, Wei-han, Li, Jun-xiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499399/ https://www.ncbi.nlm.nih.gov/pubmed/26221176 http://dx.doi.org/10.1155/2015/715638

Ejemplares similares

Update on Pparγ and Nonalcoholic Fatty Liver Disease
por: Ables, Gene P.
Publicado: (2012)

Network Pharmacology-Based Analysis of Gegenqinlian Decoction Regulating Intestinal Microbial Activity for the Treatment of Diarrhea
por: Li, Xiaoya, et al.
Publicado: (2021)

Sijunzi, Lizhong, and Fuzilizhong Decoction Alleviate Nonalcoholic Fatty Liver Disease through Activation of PPAR Pathway
por: Yang, Jiayao, et al.
Publicado: (2020)

Metabonomic analysis of plasma biochemical changes in pyrexia rats after treatment with Gegenqinlian decoction, aspirin and itraconazole by UHPLC-FT-ICR-MS
por: Liu, Ting, et al.
Publicado: (2020)

Gastrodin Reduces Blood Pressure by Intervening with RAAS and PPARγ in SHRs
por: Liu, Wei, et al.
Publicado: (2015)

Regulation of PPAR-γ activity in lipid-laden hepatocytes affects macrophage polarization and inflammation in nonalcoholic fatty liver disease
por: Li, Xiao-Yun, et al.
Publicado: (2022)

Palmitate-induced Regulation of PPARγ via PGC1α: a Mechanism for Lipid Accumulation in the Liver in Nonalcoholic Fatty Liver Disease
por: Maruyama, Hitoshi, et al.
Publicado: (2016)

Lanzhang Granules Ameliorate Nonalcoholic Fatty Liver Disease by Regulating the PPARα Signaling Pathway
por: Huang, Ping, et al.
Publicado: (2022)

Fatty Acid Synthase Inhibitor Platensimycin Intervenes the Development of Nonalcoholic Fatty Liver Disease in a Mouse Model
por: Su, Meng, et al.
Publicado: (2021)

LC-MS/MS determination and pharmacokinetics study of puerarin and daidzein in rat plasma after oral administration of Gegenqinlian decoction and Radix Puerariae extract
por: Zhang, Yifan, et al.
Publicado: (2014)

The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease
por: Kumar, Divya P., et al.
Publicado: (2020)

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis †
por: Yamashita, Shizuya, et al.
Publicado: (2023)

Effect of miR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease
por: Ding, Jiexia, et al.
Publicado: (2015)

Exploring the Protective Effects and Mechanism of Huaji Jianpi Decoction against Nonalcoholic Fatty Liver Disease by Network Pharmacology and Experimental Validation
por: Xue, Hongkun, et al.
Publicado: (2022)

Identify Molecular Mechanisms of Jiangzhi Decoction on Nonalcoholic Fatty Liver Disease by Network Pharmacology Analysis and Experimental Validation
por: Wang, Lei, et al.
Publicado: (2020)

Hyodeoxycholic acid ameliorates nonalcoholic fatty liver disease by inhibiting RAN-mediated PPARα nucleus-cytoplasm shuttling
por: Zhong, Jing, et al.
Publicado: (2023)

Evaluation of the Mechanism of Modified Lingguizhugan Decoction in the Treatment of Nonalcoholic Fatty Liver Disease
por: Yang, Fuyuan, et al.
Publicado: (2022)

Yinchen Linggui Zhugan Decoction Ameliorates Nonalcoholic Fatty Liver Disease in Rats by Regulating the Nrf2/ARE Signaling Pathway
por: Guo, Yi, et al.
Publicado: (2017)

Role of Apolipoprotein A1 in PPAR Signaling Pathway for Nonalcoholic Fatty Liver Disease
por: Chen, Changxi, et al.
Publicado: (2022)

Sini Decoction Intervention on Atherosclerosis via PPARγ-LXRα-ABCA1 Pathway in Rabbits
por: Ju, Shicong, et al.
Publicado: (2018)

Association of TNF-α, IGF-1, and IGFBP-1 levels with the severity of osteopenia in mice with nonalcoholic fatty liver disease
por: Wang, Tong-Hao, et al.
Publicado: (2023)

Erratum to “Evaluation of the Mechanism of Modified Lingguizhugan Decoction in the Treatment of Nonalcoholic Fatty Liver Disease”
por: Yang, Fuyuan, et al.
Publicado: (2022)

Co-exposure to multi-walled carbon nanotube and lead ions aggravates hepatotoxicity of nonalcoholic fatty liver via inhibiting AMPK/PPARγ pathway
por: Liu, Enqin, et al.
Publicado: (2020)

Lentinan Protects against Nonalcoholic Fatty Liver Disease by Reducing Oxidative Stress and Apoptosis via the PPARα Pathway
por: Du, Tingyi, et al.
Publicado: (2022)

Hepatocyte-Secreted Autotaxin Exacerbates Nonalcoholic Fatty Liver Disease Through Autocrine Inhibition of the PPARα/FGF21 Axis
por: Qiu, Han, et al.
Publicado: (2022)

Intervention of Shugan Xiaozhi Decoction on Nonalcoholic Fatty Liver Disease via Mediating Gut-Liver Axis
por: Yang, Huili, et al.
Publicado: (2022)

Protective Effects and Mechanisms of Yinchen Linggui Zhugan Decoction in HFD-Induced Nonalcoholic Fatty Liver Disease Rats Based on Network Pharmacology and Experimental Verification
por: Jiang, Hui, et al.
Publicado: (2022)

Shugan Xiaozhi Decoction Attenuates Nonalcoholic Steatohepatitis by Enhancing PPARα and L-FABP Expressions in High-Fat-Fed Rats
por: Xing, Yu-feng, et al.
Publicado: (2016)

Wendan decoction in the treatment of nonalcoholic fatty liver disease: A systematic review and meta-analysis
por: Zhang, Yufeng, et al.
Publicado: (2022)

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
por: Jain, Mukul R., et al.
Publicado: (2017)

Idebenone and coenzyme Q(10) are novel PPARα/γ ligands, with potential for treatment of fatty liver diseases
por: Tiefenbach, Jens, et al.
Publicado: (2018)

YiQi YangYin Decoction Attenuates Nonalcoholic Fatty Liver Disease in Type 2 Diabetes Rats
por: Li, Fengjin, et al.
Publicado: (2021)

Gegen Qinlian Decoction Coordinately Regulates PPARγ and PPARα to Improve Glucose and Lipid Homeostasis in Diabetic Rats and Insulin Resistance 3T3-L1 Adipocytes
por: Tu, Jun, et al.
Publicado: (2020)

The Effects of PPAR Agonists on Atherosclerosis and Nonalcoholic Fatty Liver Disease in ApoE(−/−)FXR(−/−) Mice
por: Lee, Yenna, et al.
Publicado: (2021)

Modes-of-Action Related to Repeated Dose Toxicity: Tissue-Specific Biological Roles of PPARγ Ligand-Dependent Dysregulation in Nonalcoholic Fatty Liver Disease
por: Al Sharif, Merilin, et al.
Publicado: (2014)

Rab2A regulates the progression of nonalcoholic fatty liver disease downstream of AMPK-TBC1D1 axis by stabilizing PPARγ
por: Chen, Zi-Yue, et al.
Publicado: (2022)

Swimming exercise ameliorates insulin resistance and nonalcoholic fatty liver by negatively regulating PPARγ transcriptional network in mice fed high fat diet
por: Zhang, Yong, et al.
Publicado: (2023)

Effects of Qutanhuoxue Decoction on AQP7 and AQP9 Expression in Nonalcoholic Fatty Liver Model Rats
por: Zheng, Ding, et al.
Publicado: (2019)

Xuefu Zhuyu decoction for nonalcoholic fatty liver disease: A protocol for systematic review and meta-analysis
por: Liu, Jiaxin, et al.
Publicado: (2021)

Xiaochaihu decoction for nonalcoholic fatty liver disease: A protocol for a systematic review and meta-analysis
por: Zhu, Wenyu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dqaha6codfqt7vb2qu4m74mgnn